TrialDiabetes & metabolism journal2026

Efficacy and Safety of HD-6277, a Novel G Protein-Coupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical Trial.

Yong-Ho Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.